January 29, 2022
Complete Omics Inc. announces its critical role in a landmark Science Advances publication identifying human endogenous retrovirus (HERV)–derived neoantigens as a new, scalable class of cancer immunotherapy targets.
From Private Mutations to Shared Tumor-Specific Antigen Classes
The first wave of precision immunotherapy focused on mutation-derived neoantigens — powerful but largely patient-specific.
The HERV discovery introduces a structurally different opportunity:
- Embedded viral sequences already present in the human genome
- Epigenetically silent in normal tissue
- Reactivated selectively in tumors
- Capable of generating shared, HLA-presented epitopes
- Amenable to scalable vaccine and cellular therapy strategies
This transforms the economic and therapeutic profile of neoantigen targeting.
Instead of building one therapy per patient, we can potentially build platforms around shared tumor-restricted targets.
Complete Omics offers the enabling platform
Breakthrough target classes do not translate without measurement, validation, and cross-layer integration.
Complete Omics served as the multi-omics validation engine that enabled this discovery to move from hypothesis to functional immunologic proof.
Our capabilities integrated:
- Transcriptomic detection of aberrant HERV activation
- Computational epitope prioritization
- HLA presentation validation
- Proteomic confirmation
- Functional T-cell reactivity analysis
This convergence — genomics × proteomics × immunology × quantitative validation — is where very few companies operate. Complete Omics does.
Immunotherapy is entering its second structural evolution. The first wave proved that mutation-derived neoantigens are actionable. The next wave expands the antigen universe itself.
HERV-derived neoantigens represent a new category. At Complete Omics, we are building the platform that discovers, validates, and quantitatively measures these next-generation targets — transforming emerging biology into investable therapeutic programs.
—Qing
Why This Matters?
The HERV finding signals three structural opportunities:
1. Expansion of the Targetable Oncology Universe
Tumors with low mutational burden may still express immunologically targetable HERV epitopes.
2. Shared Antigen Economics
Shared targets create scalable product strategies: vaccines, TCR therapies, bispecifics.
3. Companion Diagnostic Leverage
Novel antigen classes require ultra-sensitive validation platforms. Complete Omics is building that measurement layer.
Vision
The identification of HERV-derived neoantigens is more than a scientific milestone — it signals the expansion of the cancer immunotherapy addressable market into previously untapped antigen space. As oncology moves toward precision antigen engineering, the companies that control discovery, validation, and quantitative measurement will define the next decade of therapeutic innovation. Complete Omics is building that foundational layer — a scalable multi-omics platform capable of converting emerging antigen biology into validated, actionable immunotherapy programs. We believe this marks the beginning of a new era: one where the antigen universe expands beyond mutations, and where Complete Omics stands at the center of transforming unconventional biology into next-generation precision therapeutics.
